Prokarium Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 24
Employees
  • Latest Deal Type
  • Series C
  • (Upcoming)
  • Investors
  • 9

Prokarium General Information

Description

Developer of biopharmaceutical products intended to unlock the next level within immuno-oncology by building on the cutting-edge advances in cancer immunology. The company is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects, enabling doctors to combat diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • London Bioscience Innovation Centre
  • 2 Royal College Street
  • London NW1 0NH
  • England, United Kingdom

Prokarium Timeline

20182019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Prokarium Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series C) 01-Jan-2022 Upcoming Generating Revenue
8. Later Stage VC (Series B) 27-Oct-2020 000.00 000.00 0000 Completed Clinical Trials - Phase 1
7. Later Stage VC 08-Oct-2019 00.00 0000 Completed Pre-Clinical Trials
6. Later Stage VC (Series A) 26-Feb-2018 000.00 000.00 000.00 Completed Pre-Clinical Trials
5. Later Stage VC 000.00 Completed Pre-Clinical Trials
4. Grant 25-Jul-2016 00.000 000.00 Completed Pre-Clinical Trials
3. Corporate 19-Aug-2015 00000 000.00 Completed Pre-Clinical Trials
2. Seed Round 01-Feb-2014 $9.9M $9.9M Completed Startup
1. Grant 11-Mar-2013 $343K Completed Pre-Clinical Trials
To view Prokarium’s complete valuation and funding history, request access »

Prokarium Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 000,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 6,700 $0.012961 $2581.47 $2581.47 1x $2581.47 0.24%
To view Prokarium’s complete cap table history, request access »

Prokarium Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of biopharmaceutical products intended to unlock the next level within immuno-oncology by building on the cutt
Drug Discovery
London, United Kingdom
24 As of 2021
000.00
00000000000

00000000

re et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi u
0000 000000000
Schlieren, Switzerland
00 As of 0000
000.00
00000000000 000.00

00000000

eniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute
0000 000000000
Rockville, MD
00 As of 0000
00000
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Prokarium Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Redbiotec Venture Capital-Backed Schlieren, Switzerland 00 000.00 00000000000 000.00
000000000 00000000 Venture Capital-Backed Rockville, MD 00 00000 0000000000 0 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
00 000000 Venture Capital-Backed Basel, Switzerland 00 000.00 0000000000 0 000.00
000000 & 00 Formerly VC-backed Seongnam, South Korea 00 00000 00000000 00000
You’re viewing 5 of 31 competitors. Get the full list »

Prokarium Executive Team (6)

Name Title Board Seat Contact Info
Kristen Albright Ph.D Chief Executive Officer
Livija Deban Ph.D Vice President
Uz Stammberger Ph.D Chief Medical Officer
You’re viewing 3 of 6 executive team members. Get the full list »

Prokarium Board Members (9)

Name Representing Role Since
Allan Jarvis Prokarium Board Member 000 0000
Carl-Johan Spak Ph.D Flerie Invest Board Member 000 0000
Hyam Levitsky Self Board Member & Advisor 000 0000
Khalid Al Saleh Ph.D Riyadh Valley Company Board Member 000 0000
Sangwoo Lee Prokarium Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Prokarium Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Prokarium Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
British Business Bank Business Development Company Minority 000 0000 000000 0
Government of UK Government Minority 000 0000 000000 0
Wellcome Trust Limited Partner Minority 000 0000 000000 0
Korea Investment Partners Venture Capital Minority 000 0000 000000 0
Riyadh Valley Company Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »